Human biodistribution and radiation dosimetry of the demyelination tracer [ 18 F]3F4AP

Pedro Brugarolas, Moses Q. Wilks, Jacqueline Noel, Julia-Ann Kaiser, Danielle R. Vesper, Karla M. Ramos‐Torres, Nicolas J. Guehl, Marina T. Macdonald-Soccorso, Peter A. Rice, Daniel Yokell, Ruth Lim, Marc D. Normandin, Georges El FakhrimedRxiv 2022 · DOI

This paper details the first-in-human study of a promising new PET (Positron Emission Tomography) radiotracer, [$^{18}$F]3F4AP, designed to visualize demyelination—the hallmark of diseases like Multiple Sclerosis (MS). By confirming that the tracer is safe and carries a low radiation burden, the researchers have cleared a major hurdle for its use in clinical diagnostic trials.

TL;DR

Researchers successfully conducted the first human trials of [$^{18}$F]3F4AP, a PET tracer that targets exposed potassium channels in demyelinated nerves. The study found the tracer to be safe, fast-clearing, and associated with a lower radiation dose than the current "gold standard" PET tracers, paving the way for its use in imaging Multiple Sclerosis.

What Problem Does This Paper Address?

In a healthy brain, nerve fibers (axons) are insulated by a fatty layer called myelin. In diseases like Multiple Sclerosis, this insulation is stripped away. When demyelination occurs, voltage-gated potassium ($K^+$) channels that are normally "buried" under the myelin become exposed and overexpressed. This leads to electrical signal leakage and the neurological symptoms associated with MS.

While MRI is excellent at spotting lesions in the brain, it isn't always specific about the underlying molecular pathology—it can be hard to tell if a lesion is actively demyelinated, remyelinating, or just inflamed. [$^{18}$F]3F4AP is a radiofluorinated version of the MS drug 4-aminopyridine (4AP). It binds specifically to these exposed $K^+$ channels, potentially offering a direct, molecular "map" of demyelination in living patients. Before this can be used in patients, however, researchers must prove it is safe and calculate the radiation dose humans receive from it (dosimetry).

Methods

The study involved four healthy volunteers (two male, two female). After receiving an intravenous injection of the tracer, participants underwent a 4-hour dynamic PET/CT scan covering the body from the head to the mid-thigh.

Key methodological points include:

  • Dynamic Imaging: The 4-hour window allowed researchers to track the "kinetics" of the tracer—how fast it enters organs and how quickly it leaves.
  • Manual VOIs: Researchers manually drew "Volumes of Interest" around 20+ different organs on the CT/PET scans to calculate the specific radioactivity concentration in each.
  • Dosimetry Modeling: They used OLINDA software, a standard tool in nuclear medicine, to integrate the time-activity curves and estimate the total effective radiation dose.
  • Safety Monitoring: Beyond imaging, the team performed blood tests (Comprehensive Metabolic Panels), ECGs, and vital sign monitoring before and after the scans.

Datasets

As a first-in-human safety and dosimetry study, the primary "dataset" is the cohort of four healthy human volunteers (ages 24–59). The researchers compared their human results against previous datasets from:

  • Nonhuman Primates (NHPs): Specifically rhesus macaques, which were used in earlier preclinical trials.
  • Standard Tracers: Comparison data for [$^{18}$F]FDG (the most common PET tracer used in oncology and neurology).

Key Insights and Ideas

  • The "Anesthesia Effect": One of the most striking findings was that the tracer cleared from the blood significantly faster in humans than it did in monkeys. The authors suggest this might be because the monkeys were anesthetized during their scans, which slows down metabolism and renal clearance, whereas the human volunteers were awake.
  • Renal Excretion is King: The tracer is primarily excreted through the kidneys and bladder. This is good news for brain imaging, as it means the "background" radiation in the rest of the body clears out quickly.
  • Image-Derived Input Functions: The researchers found that the radioactivity concentration measured directly from the heart's left ventricle in the PET images matched the concentration found in actual venous blood samples. This suggests that future studies might be able to avoid invasive blood sampling by using the PET images themselves to model how the drug moves through the body.

Key Results

  • Low Radiation Dose: The average effective dose (ED) was 12.1 ± 2.2 µSv/MBq. This is notably lower than the dose from the standard [$^{18}$F]FDG (~20 µSv/MBq) and much lower than the 21.6 µSv/MBq predicted by animal models.
  • Safety: No adverse events were reported. Vital signs, blood work, and ECGs remained stable, indicating the tracer is well-tolerated at the microgram doses used for imaging.
  • Organ Distribution: The highest activity was seen in the kidneys, urinary bladder, stomach, liver, and brain. Crucially, there was very low accumulation in fat and muscle, which improves the signal-to-noise ratio for imaging.

Limitations and Future Work

The most obvious limitation is the small sample size ($n=4$), though this is standard for initial dosimetry studies. Furthermore, because the participants were healthy volunteers, the study does not yet demonstrate the tracer's ability to "light up" demyelinated lesions in humans—that is the goal of the next phase of clinical trials.

Future work will focus on applying [$^{18}$F]3F4AP to patients with Multiple Sclerosis and other demyelinating conditions to see if the tracer's sensitivity to $K^+$ channels translates into a superior diagnostic tool for monitoring disease progression and treatment response.

Summary updated

Abstract

Abstract Purpose [ 18 F]3F4AP is a novel PET radiotracer that targets voltage-gated potassium (K + ) channels and has shown promise for imaging demyelinated lesions in animal models of neurological diseases. This study aimed to evaluate the biodistribution, safety and radiation dosimetry of [ 18 F]3F4AP in healthy human volunteers. Methods Four healthy volunteers (2 female) underwent a 4-hour dynamic PET scan from cranial vertex to mid-thigh using multiple bed positions after administration of 368 ± 17.9 MBq (9.94 ± 0.48 mCi) of [ 18 F]3F4AP was produced in a cGMP laboratory under IND authorization from the FDA. Volumes of interest for relevant organs were manually drawn guided by the CT and PET images and time-activity curves (TACs) were extracted. Radiation dosimetry was estimated from the integrated TACs using OLINDA software. Safety assessments included measuring vital signs immediately before and after the scan, monitoring for adverse events, as well as obtaining a comprehensive metabolic panel (CMP) and electrocardiogram (ECG) within 30 days before and after the scan. The study was approved by the institutional review board (IRB) and registered at clinicaltrials.gov ( NCT04710550 ) before commencement. Results [ 18 F]3F4AP distributed throughout the body with the highest levels of activity in the kidneys, urinary bladder, stomach, liver, spleen and brain and with low accumulation in muscle and fat. The tracer cleared quickly from circulation and from most organs. The clearance of the tracer was noticeably faster than previously reported clearance in nonhuman primates (NHPs). The average effective dose (ED) across all subjects was 12.1 ± 2.2 µSv/MBq, which is lower than the estimated ED from the NHP studies (21.6 ± 0.6 µSv/MBq) as well as the ED of other fluorine-18 radiotracers such as [ 18 F]FDG (∼20 µSv/MBq). No differences in ED between males and females were observed. No substantial changes in safety assessments or adverse events were recorded. Conclusion The biodistribution and radiation dosimetry of [ 18 F]3F4AP in humans is reported for the first time. The average total ED across four subjects was lower than most 18 F-labeled PET tracers. The tracer and study procedures were well tolerated and no adverse events occurred.
BibTeX
@misc{brugarolas2022human,
  author = {Pedro Brugarolas and Moses Q. Wilks and Jacqueline Noel and Julia-Ann Kaiser and Danielle R. Vesper and Karla M. Ramos‐Torres and Nicolas J. Guehl and Marina T. Macdonald-Soccorso and Peter A. Rice and Daniel Yokell and Ruth Lim and Marc D. Normandin and Georges El Fakhri},
  title = {{Human biodistribution and radiation dosimetry of the demyelination tracer [ <sup>18</sup> F]3F4AP}},
  year = {2022},
  doi = {10.1101/2022.05.21.22275275},
  howpublished = {medRxiv},
}

Loading related content...

Figure